- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03530306
Treatment Evaluation of Neuromodulation for Tinnitus - Stage A2 (TENT-A2)
September 26, 2022 updated by: Neuromod Devices Ltd.
Treatment Evaluation of Neuromodulation for Tinnitus - Stage A2 (TENT-A2)
This is a four arm, patient subtyping and parameter optimisation study for a neuromodulation treatment for tinnitus.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Participants with chronic tinnitus will be provided with a CE marked neuromodulation device.
Participants are randomized to one of four different treatment arms.
The treatment period is intended for 12 weeks of use.
Based on the clinical investigation plan, participants are informed that their stimulation settings can change between the first and second halves of the treatment period and that the differences may be perceptually noticeable.
Differences in tinnitus severity scores will be compared between and within treatment arms.
Study Type
Interventional
Enrollment (Actual)
191
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dublin, Ireland
- St. James's Wellness Trust Clinical Research Facility
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 to 70 years of age
- Ability to read and understand English
- Willing and able to provide informed consent
- Willing to commit to the full duration of the study
- Baseline Tinnitus Handicap Inventory (THI) score of >= 38 points
- Subjective tinnitus of 3 months to 10 years
- Maximum AC pure-tone audiometry hearing loss of 80 dB HL in any test frequency in the set {2,3,4,6,8}kHz or 40 dB HL in the set {250,500,1000}Hz either unilaterally or bilaterally
- Baseline Minimum Masking Level (MML) of 20 to 80 dB HL
- Tonal tinnitus
Exclusion Criteria:
- Diagnosed with objective tinnitus
- Commenced usage of hearing aid within the last 90 days
- Cases where pulsatility is the dominant feature of tinnitus
- Patients whose tinnitus cannot be masked during Minimum Masking Level (MML) assessment
- Meniere's disease
- Significantly severe Loudness Discomfort Level (LDL, less than 30 dB SL)
- Depression or neuro-psychological condition, previously diagnosed or identified from the State-Trait Anxiety Inventory (STAI) with score greater than 120
- Diagnosed with somatic tinnitus resulting from head or neck injury
- Temporomandibular Joint Disorder (TMJ)
- Current or previous involvement in medico-legal cases
- Pregnancy
- Oral piercings
- Neurological condition that may lead to loss of consciousness (e.g. epilepsy) or is considered to be the dominant feature of the tinnitus, as assessed by audiologist or ENT consultant
- Severe cognitive impairment based on Mini Mental State Examination (MMSE, less than 20)
- Patient with a pacemaker or other electro-active implanted device
- Have used Neuromod Devices products in the past
- Participants currently prescribed drugs for a central nervous system pathology, i.e. epilepsy, Multiple Sclerosis (MS), Parkinson's, bi-polar disorder
- The site Principal Investigator does not deem the candidate to be suitable for the study for other reasons not listed above
- Self-reporting episodes of auditory hallucinations
- Abnormal Otoscopy as assessed by the Audiologist, including active Otitis Media, perforation and hearing loss that is identified as completely conductive
- Abnormal Tympanometry as assessed by the Audiologist
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: PS1-PS4
|
Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment.
During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
|
Active Comparator: PS6-PS10
|
Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment.
During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
|
Active Comparator: PS7-PS4
|
Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment.
During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
|
Active Comparator: PS9-PS6
|
Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment.
During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tinnitus Handicap Inventory (THI)
Time Frame: Between-arm and within-arm changes in THI after 6 weeks of treatment
|
Between-arm and within-arm changes in THI after 6 weeks of treatment
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tinnitus Handicap Inventory (THI)
Time Frame: Between-arm and within-arm changes in THI after 12 weeks of treatment
|
Between-arm and within-arm changes in THI after 12 weeks of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mr. Brendan Conlon, St. James's Hospital, Dublin
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 20, 2018
Primary Completion (Actual)
October 2, 2018
Study Completion (Actual)
July 18, 2019
Study Registration Dates
First Submitted
May 8, 2018
First Submitted That Met QC Criteria
May 8, 2018
First Posted (Actual)
May 21, 2018
Study Record Updates
Last Update Posted (Actual)
September 28, 2022
Last Update Submitted That Met QC Criteria
September 26, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Neuromoddevices TENT-A2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tinnitus
-
State University of New York at BuffaloUniversity at BuffaloCompletedTinnitus, Subjective | Tinnitus | Noise Induced Tinnitus | Tinnitus, Objective | Tinnitus Aggravated | Tinnitus, Pulsatile | Tinnitus, Spontaneous Oto-Acoustic Emission | Tinnitus, Clicking | Tinnitus, Tensor Tympani InducedUnited States
-
Mohab MohammedNot yet recruitingPulsatile Tinnitus (Diagnosis)
-
Philipps University Marburg Medical CenterLinkoeping University; Eriksholm Research Centre; University Hospital of Gießen...CompletedTinnitus | Subjective Tinnitus | Chronic TinnitusGermany
-
University of GuadalajaraHospital Civil de Guadalajara; Institute of Experimental and Clinical TherapeuticsRecruitingOxidative Stress | Tinnitus, Subjective | Tinnitus, Bilateral | Antioxidant Therapy | Psychiatric Drugs | Inflammatory Cytokines | SSRIMexico
-
University Hospital, BordeauxNot yet recruiting
-
Cairo UniversityRecruiting
-
University of ZurichRecruitingTinnitus, Subjective | TinnitusSwitzerland
-
Eye & ENT Hospital of Fudan UniversityNot yet recruiting
-
University of Illinois at Urbana-ChampaignGN Hearing A/SActive, not recruitingTinnitus, SubjectiveUnited States
-
University of ZurichCompletedTinnitus, SubjectiveGermany, Switzerland
Clinical Trials on PS1-PS4
-
University of MinnesotaNeuromod Devices Limited; Kent TaylorActive, not recruiting
-
Neuromod Devices Ltd.University Hospital RegensburgCompleted
-
Pharmasaga Co. Ltd.Recruiting
-
Universidad Complutense de MadridHospital General Universitario Gregorio Marañon; Gerencia de Atención Primaria...Completed